Ganoderma Microsporum Immunomodulatory Protein (Gmi) is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Ganoderma Microsporum Immunomodulatory Protein (Gmi) directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Ganoderma Microsporum Immunomodulatory Protein (Gmi) remains protective as scientific knowledge develops.
Study duration uncertainty factor F3 in PDE derivation for Ganoderma Microsporum Immunomodulatory Protein (Gmi) compensates for the data gap between the duration of available toxicology studies and the chronic lifetime pharmaceutical exposure scenario.
